Bluebird Confident In Financial Runway For Skysona Launch
No Outcomes-Based Agreements Planned
Executive Summary
The $3m gene therapy for the rare disease cerebral adrenoleukodystrophy marks bluebird’s second approval in just under a month.
You may also be interested in...
Bluebird’s Zynteglo Launch Under Way, But First Revenue Will Take Months
Bluebird bio will not see revenue for Zynteglo until it is infused into beta-thalassemia patients, which will take months due to the ex vivo gene therapy’s complex manufacturing and quality control process.
Bluebird’s Zynteglo Approval Kicks Off Commercial Operations
Bluebird bio’s Tom Klima told Scrip launch preparations are well under way, including negotiations with payers on outcomes-based reimbursement agreements.
Bluebird Bio Restructures Amid Financial Woes, But Will It Fly?
The firm is laying off a big piece of its workforce and deprioritizing some investments to free up capital for potential upcoming launches, but that could add commercial risks.